Dublin, Ireland, 13 May 2024: ERS Genomics Limited (‘ERS’), the CRISPR licensing company, today announced the appointment of John E Milad as CEO, with immediate effect. John brings over 25 years of experience as an executive leader, venture capitalist, and investment banker focused on the life sciences and medical technology sectors. As CEO of Quanta Dialysis Technologies for nearly a decade, John led the development and commercial launch of an award-winning portable haemodialysis system designed to transform the delivery of kidney care to patients. He drove market entry into the UK and US, while raising a record-breaking $245 million private